Trial Profile
Phase I study of CC-5013 (lenalidomide, NSC 703813, IND 70116) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndromes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.